X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1683) 1683
animals (1160) 1160
diabetes mellitus, type 2 - drug therapy (1003) 1003
glucose (992) 992
male (948) 948
diabetes (816) 816
endocrinology & metabolism (806) 806
sodium-glucose transporter 2 - antagonists & inhibitors (733) 733
hypoglycemic agents - therapeutic use (663) 663
type 2 diabetes (661) 661
female (641) 641
glucose - metabolism (554) 554
dextrose (532) 532
dapagliflozin (526) 526
diabetes mellitus (517) 517
sodium-glucose transporter 2 - metabolism (478) 478
sodium (455) 455
glucosides - therapeutic use (448) 448
middle aged (444) 444
double-blind (431) 431
empagliflozin (411) 411
sodium-glucose transporter 1 - metabolism (407) 407
insulin (394) 394
pharmacology & pharmacy (388) 388
rats (380) 380
blood glucose - metabolism (362) 362
canagliflozin (354) 354
hypoglycemic agents - adverse effects (335) 335
hypoglycemic agents - pharmacology (333) 333
treatment outcome (326) 326
hyperglycemia (309) 309
benzhydryl compounds - therapeutic use (306) 306
diabetes mellitus, type 2 - blood (306) 306
mice (305) 305
physiology (296) 296
aged (291) 291
sglt2 inhibitor (288) 288
diabetes mellitus, type 2 - metabolism (286) 286
sodium-glucose transporter 1 (283) 283
blood glucose - drug effects (278) 278
safety (272) 272
adult (270) 270
analysis (267) 267
glucosides - pharmacology (267) 267
sodium-glucose transporter 2 inhibitors - therapeutic use (263) 263
glycemic control (258) 258
metformin (252) 252
type 2 diabetes mellitus (249) 249
diabetes mellitus, type 2 - complications (247) 247
risk factors (241) 241
glucose metabolism (239) 239
expression (232) 232
sglt2 inhibitors (230) 230
blood pressure (225) 225
type-2 diabetes-mellitus (219) 219
biochemistry & molecular biology (217) 217
clinical trials (216) 216
kidney - metabolism (216) 216
metabolism (215) 215
hypoglycemic agents (213) 213
hypoglycemic agents - administration & dosage (213) 213
glucosides - adverse effects (209) 209
sodium-glucose transporter 1 - genetics (207) 207
mellitus (205) 205
care and treatment (204) 204
glucose transporter (204) 204
mortality (201) 201
monosaccharide transport proteins - metabolism (199) 199
inadequate glycemic control (198) 198
efficacy (197) 197
cardiovascular outcomes (188) 188
research (187) 187
internal medicine (184) 184
sglt1 (180) 180
cardiac & cardiovascular systems (179) 179
body weight (178) 178
drug therapy (177) 177
heart failure (177) 177
benzhydryl compounds - pharmacology (173) 173
medicine & public health (171) 171
sodium-glucose transporter 2 inhibitors (170) 170
membrane glycoproteins - metabolism (167) 167
inhibitors (166) 166
kidney (164) 164
blood-pressure (162) 162
glycated hemoglobin a - metabolism (162) 162
rodents (162) 162
sglt2 (162) 162
sodium - metabolism (159) 159
drug therapy, combination (157) 157
diabetes therapy (155) 155
insulin resistance (152) 152
kidney - drug effects (150) 150
risk (146) 146
absorption (145) 145
benzhydryl compounds - adverse effects (144) 144
abridged index medicus (143) 143
patients (141) 141
dose-response relationship, drug (140) 140
physiological aspects (140) 140
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2636) 2636
Japanese (30) 30
German (24) 24
Korean (11) 11
Spanish (11) 11
Chinese (7) 7
French (7) 7
Russian (7) 7
Czech (3) 3
Dutch (2) 2
Portuguese (2) 2
Swedish (2) 2
Danish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Polish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PloS one, ISSN 1932-6203, 2013, Volume 8, Issue 2, p. e54442
Sodium/glucose cotransporter 2 (SGLT2) inhibitors are oral hypoglycemic agents used to treat patients with diabetes mellitus... 
MATRIX | STIMULATION | MULTIDISCIPLINARY SCIENCES | DISEASE | HIGH GLUCOSE | GENE-EXPRESSION | PPAR-GAMMA AGONISTS | TRANSFORMING GROWTH FACTOR-BETA | Diabetes Mellitus - pathology | Epithelial Cells - metabolism | Gene Expression - drug effects | Diabetes Mellitus - genetics | Transcription Factor AP-1 - genetics | Epithelial Cells - drug effects | Humans | Diabetic Nephropathies - drug therapy | NF-kappa B - metabolism | Smad3 Protein - metabolism | Transcription Factor AP-1 - metabolism | Sodium-Glucose Transporter 1 - genetics | Smad3 Protein - genetics | Sodium-Glucose Transporter 1 - metabolism | Phosphorylation - drug effects | Interleukin-6 - metabolism | Transforming Growth Factor beta1 - pharmacology | Sodium-Glucose Transporter 2 - genetics | Collagen Type IV - metabolism | Sodium-Glucose Transporter 1 - antagonists & inhibitors | Promoter Regions, Genetic | Diabetic Nephropathies - pathology | Glucosides - pharmacology | Kidney Tubules, Proximal - pathology | Interleukin-6 - genetics | Sodium-Glucose Transporter 2 - metabolism | Diabetic Nephropathies - metabolism | Diabetes Mellitus - drug therapy | Diabetes Mellitus - metabolism | Toll-Like Receptor 4 - genetics | Diabetic Nephropathies - genetics | Epithelial Cells - pathology | Glucose - pharmacology | Toll-Like Receptor 4 - metabolism | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | NF-kappa B - genetics | Kidney Tubules, Proximal - metabolism | Collagen Type IV - genetics | Protein Binding | Benzhydryl Compounds - pharmacology | Kidney Tubules, Proximal - drug effects | Physiological aspects | Care and treatment | Genetic aspects | Research | Transforming growth factors | Diabetic nephropathies | Chromatin | Immunoprecipitation | Transforming growth factor-b | Interleukin | Clinical trials | Systematic review | Smad3 protein | Glucose | Kinases | Interleukin 6 | Proteins | Hyperglycemia | Rodents | Toll-like receptors | Collagen (type IV) | Hypoglycemic agents | Inhibition | Growth factors | Deoxyribonucleic acid--DNA | Immune system | Binding | Glucose transporter | Medical research | NF-κB protein | Diabetes mellitus | Markers | Activator protein 1 | Blocking | Reabsorption | Inflammation | Gene expression | Glucose transport | Medicine | High mobility group proteins | Hospitals | Inhibitors | Nephropathy | Sodium | Fibrosis | Kidney diseases | Diabetes | Transporter | Adenosine triphosphatase | Kidney transplantation | Deoxyribonucleic acid | DNA
Journal Article
PloS one, ISSN 1932-6203, 02/2012, Volume 7, Issue 2, p. e30555
Background: Canagliflozin is a sodium glucose co-transporter (SGLT) 2 inhibitor in clinical development for the treatment of type 2 diabetes mellitus (T2DM). Methods... 
SELECTIVE SGLT2 INHIBITOR | SODIUM | HOMEOSTASIS | HYPERGLYCEMIA | DAPAGLIFLOZIN | TRANSPORTERS | MULTIDISCIPLINARY SCIENCES | INSULIN-SECRETION | COTRANSPORTER | PROXIMAL TUBULAR CELLS | T-1095 | Thiophenes - therapeutic use | Diabetes Mellitus, Experimental - drug therapy | Humans | Body Weight - drug effects | Male | Muscle, Skeletal - metabolism | Muscle, Skeletal - cytology | Hyperglycemia - drug therapy | Sodium-Glucose Transporter 1 - genetics | Muscle, Skeletal - drug effects | Hyperglycemia - pathology | Sodium-Glucose Transport Proteins - metabolism | Glucosides - therapeutic use | Weight Gain - drug effects | Sodium-Glucose Transporter 1 - metabolism | Diabetes Mellitus, Experimental - metabolism | Kidney - physiopathology | Sodium-Glucose Transport Proteins - genetics | CHO Cells | Sodium-Glucose Transporter 2 - genetics | Cricetinae | Glucose Tolerance Test | Kidney - drug effects | Sodium-Glucose Transporter 2 - metabolism | Mice, Inbred C57BL | Cells, Cultured | Rats | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hyperglycemia - metabolism | Rats, Zucker | Animals | Canagliflozin | Diabetes Mellitus, Experimental - pathology | Mice, Obese | Mice | Blood Glucose - metabolism | Type 2 diabetes | Glucose metabolism | Obesity | Blood sugar | Analysis | Body weight | Glycosylated hemoglobin | Diabetes therapy | Cell culture | Animal models | Renal function | Laboratories | Liver | Homeostasis | Fuel consumption | Diabetic neuropathy | Glucose | Oocytes | Hyperglycemia | Rodents | Hemoglobin | Glucose transporter | Excretion | Kidneys | Secretion | Research & development--R&D | Diabetes mellitus | Pharmacology | Insulin | Body weight gain | Myoblasts | Beta cells | Sodium | Weight reduction | Insulin resistance | Diabetes | Mutation | Transporter | Kidney transplantation | Pharmaceuticals | Research & development | R&D
Journal Article
American journal of physiology. Renal physiology, ISSN 1522-1466, 2017, Volume 313, Issue 3, pp. F826 - F834
.... In the membrane fraction of the kidney, the expression of urate transporter 1 (URAT1) was significantly decreased, whereas that of ATP-binding cassette subfamily G member 2 (ABCG2... 
Hyperinsulinemia | Urate transporters | Hypouricosuria | Kidney proximal tubule | CLEARANCE | PHYSIOLOGY | hyperinsulinemia | CARDIOVASCULAR OUTCOMES | SGLT2 INHIBITOR | HYPOURICEMIA | RISK | LEVEL | EXCRETION | IDENTIFICATION | hypouricosuria | urate transporters | UROLOGY & NEPHROLOGY | kidney proximal tubule | HYPERTENSION | ASSOCIATION | Kidney Tubules - physiopathology | Diabetes Mellitus, Experimental - drug therapy | Streptozocin | Diabetes Mellitus, Type 1 - metabolism | Male | ATP Binding Cassette Transporter, Sub-Family G, Member 2 - metabolism | Uric Acid - urine | Renal Reabsorption - drug effects | Time Factors | Diabetes Mellitus, Type 1 - chemically induced | Diabetes Mellitus, Experimental - chemically induced | Diabetes Mellitus, Experimental - metabolism | Kidney Tubules - metabolism | Diabetes Mellitus, Experimental - physiopathology | Cell Line | Insulin - pharmacology | Glucosides - pharmacology | Uric Acid - metabolism | Kidney Tubules - drug effects | Sodium-Glucose Transporter 2 - metabolism | Diabetes Mellitus, Type 1 - physiopathology | Thiophenes - pharmacology | Renal Elimination - drug effects | Anion Transport Proteins - metabolism | Rats, Sprague-Dawley | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Diabetes Mellitus, Type 1 - drug therapy | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Animals | Blood Glucose - metabolism | Carrier proteins | Physiological aspects | Physiological research | Uric acid | Research | G proteins | Insulin | Absorption (Physiology)
Journal Article
PloS one, ISSN 1932-6203, 2014, Volume 9, Issue 11, p. e108994
Background and Objective: Sodium glucose cotransporter 2 (SGLT2) is the main luminal glucose transporter in the kidney... 
CELLS | HYPERGLYCEMIA | SGLT2 | TRANSPORTERS | INFLAMMATION | MULTIDISCIPLINARY SCIENCES | DISEASE | INJURY | PPAR-GAMMA AGONISTS | TRANSFORMING GROWTH FACTOR-BETA | PROGRESSION | Benzoates - therapeutic use | Toll-Like Receptor 2 - genetics | Diabetic Nephropathies - etiology | Transforming Growth Factor beta1 - metabolism | Glucose Transporter Type 1 - metabolism | Male | RNA, Messenger - metabolism | Nitric Oxide Synthase Type III - deficiency | Glucosides - therapeutic use | Chemokine CCL2 - metabolism | Diabetes Mellitus, Experimental - chemically induced | Diabetes Mellitus, Experimental - complications | Diabetes Mellitus, Experimental - metabolism | Benzhydryl Compounds - therapeutic use | Diabetic Nephropathies - prevention & control | Benzimidazoles - therapeutic use | Sodium-Glucose Transporter 2 - genetics | Hypoglycemic Agents - therapeutic use | Glucosides - pharmacology | Kidney Tubules, Proximal - pathology | Albuminuria - etiology | Blood Glucose - analysis | Sodium-Glucose Transporter 2 - metabolism | Diabetic Nephropathies - metabolism | Mice, Inbred C57BL | Chemokine CCL2 - genetics | Transforming Growth Factor beta1 - genetics | Toll-Like Receptor 2 - metabolism | Nitric Oxide Synthase Type III - genetics | Fibronectins - metabolism | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | Mice, Knockout | Animals | Glucose Transporter Type 1 - genetics | Kidney Tubules, Proximal - metabolism | Benzoates - pharmacology | Benzimidazoles - pharmacology | Benzhydryl Compounds - pharmacology | Fibronectins - genetics | Mice | Streptozocin - toxicity | Blood Glucose - metabolism | Kidney Tubules, Proximal - drug effects | Drugs | Transcription | Syngeneic grafts | Streptozocin | Genomics | Transforming growth factor | Glucose | Macrophages | Blood | Fibronectin | Proteins | Atrophy | Hyperglycemia | Rodents | Toll-like receptors | Physiology | Inhibition | Protein transport | Immune system | Creatinine | Glucose transporter | Medical research | Kidneys | Cytokines | Diabetes mellitus | Reabsorption | Histology | Inflammation | Metabolism | Gene expression | Nephropathy | Sodium | Nitric oxide | Fibrosis | Angiotensin | Insulin resistance | Research design | Kidney diseases | Diabetes | Transporter | Monocyte chemoattractant protein 1 | Kidney transplantation | Best practice
Journal Article
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2015, Volume 112, Issue 30, pp. E4111 - E4119
Journal Article
PloS one, ISSN 1932-6203, 2016, Volume 11, Issue 11, p. e0166125
Objective Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for the treatment of diabetes... 
ADD-ON THERAPY | DIPEPTIDYL PEPTIDASE-4 INHIBITORS | LIVER-FUNCTION TESTS | SGLT2 INHIBITOR | MULTIDISCIPLINARY SCIENCES | DOUBLE-BLIND | CARDIOVASCULAR-DISEASE | METFORMIN PLUS SULFONYLUREA | JAPANESE PATIENTS | INADEQUATE GLYCEMIC CONTROL | LONG-TERM EFFICACY | Hypoglycemic Agents - therapeutic use | Sodium-Glucose Transporter 2 - metabolism | Glycated Hemoglobin A - metabolism | Humans | Sodium-Glucose Transporter 2 Inhibitors | Treatment Outcome | Diabetes Mellitus, Type 2 - metabolism | Randomized Controlled Trials as Topic | Diabetes Mellitus, Type 2 - blood | Canagliflozin - therapeutic use | Glucosides - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Type 2 diabetes | Medical research | Complications and side effects | Heart beat | Analysis | Glycosylated hemoglobin | Medicine, Experimental | Lipids | Glucose | Drug therapy | Dextrose | Diabetes therapy | Drugs | Genital tract | Pressure effects | Heart attacks | Liver | Bias | Body weight | Clinical trials | Cardiovascular disease | Systematic review | Infections | Cancer therapies | Blood | Confidence intervals | Quality | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Creatinine | Glucose transporter | Alanine | Peptidase | Liver diseases | Kidneys | Diabetes mellitus | Data processing | FDA approval | Hypoglycemia | Metabolism | Patients | Heart rate | Studies | Hospitals | Inhibitors | Sodium | Ketoacidosis | Alanine transaminase | Metformin | Diabetes | Clinical medicine | Transporter
Journal Article
PloS one, ISSN 1932-6203, 2014, Volume 9, Issue 11, p. e112394
.... Empagliflozin, as a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), offers a novel approach for the treatment of type 2 diabetes by enhancing urinary glucose excretion... 
NADPH OXIDASE | GLYCEMIC CONTROL | ORGANIC NITRATES | ENDOTHELIAL DYSFUNCTION | OXIDANT STRESS | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE | MULTIDISCIPLINARY SCIENCES | NITRIC-OXIDE | BURST ACTIVITY | GLYCATION END-PRODUCTS | SGLT-2 INHIBITOR | Benzhydryl Compounds - administration & dosage | Male | Insulin - blood | Diabetes Mellitus, Experimental | Inflammation Mediators - metabolism | Streptozocin - adverse effects | Cytokines - genetics | Receptor for Advanced Glycation End Products | Diabetic Angiopathies - metabolism | Gene Expression | Glucosides - pharmacology | Cytokines - metabolism | Signal Transduction | Diabetes Complications - metabolism | RNA, Messenger - genetics | Rats | Diabetes Complications - drug therapy | Diabetic Angiopathies - drug therapy | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Blood Glucose - drug effects | Insulin - metabolism | Animals | Glucosides - administration & dosage | Glucose - metabolism | Benzhydryl Compounds - pharmacology | Hemodynamics - drug effects | Oxidative Stress - drug effects | Receptors, Immunologic - metabolism | Type 2 diabetes | Oxidative stress | RNA | Streptozocin | Type 1 diabetes | Blood sugar | Fluorescence | Hypoglycemic agents | Health aspects | Enzyme-linked immunosorbent assay | Diabetes therapy | Drugs | Drinking water | Intravenous administration | Dehydrogenases | Staining | Diabetic neuropathy | Glucose | Blood | Isometric | Hyperglycemia | Rodents | Aorta | Oxidation | Pancreas | Cardiology | Age | Glucose transporter | Excretion | Advanced glycosylation end products | Diabetes mellitus | Blood vessels | Chemiluminescence | Inflammation | Glycosylation | Injection | Gene expression | Insulin | Studies | Polymerase chain reaction | Signaling | Inhibitors | Sodium | Islets of Langerhans | Diabetes | Laboratory animals | Transporter
Journal Article